Abstract
Background
The lacking of estrogen, progesterone and ERBB2 receptor makes the therapy of Triple negative breast cancer (TNBC) is particularly challenging. Accumulating evidences has demonstrated the dysfunction and critical roles of microRNAs (miRNAs) in TNBC.
Objective
Explore the role of miR-506-3p in TNBC and evaluate the clinical significance of miR-506-3p.
Results
miR-506-3p expression was significantly decreased in TNBC and correlated with the worst status of TNBC patients. miR-506-3p overexpression repressed the proliferation, migration and induced cell cycle arrest as well as apoptosis of TNBC cells. Mechanistically, SNAI2 was identified as a target of miR-506-3p in TNBC cells. Consistently, SNAI2 was overexpressed in TNBC and inversely correlated with miR-506-3p level. Transfection of SNAI2 abolished the inhibitory role of miR-506-3p in regulating the malignant phenotypes of TNBC cells.
Conclusions
These results demonstrated the suppressive function of miR-506-3p in TNBC via targeting SNAI2, indicating the possible application of miR-506-3p in TNBC treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alves CC, Carneiro F, Hoefler H, Becker KF (2009) Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci (landmark Ed) 14:3035–3050. https://doi.org/10.2741/3433
Alves CL, Elias D, Lyng MB, Bak M, Ditzel HJ (2018) SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res 20:60. https://doi.org/10.1186/s13058-018-0988-9
Barry P et al (2018) The spatiotemporal evolution of lymph node spread in early breast cancer. Clin Cancer Res 24:4763–4770. https://doi.org/10.1158/1078-0432.CCR-17-3374
Benfey PN (2003) Molecular biology: microRNA is here to stay. Nature 425:244–245. https://doi.org/10.1038/425244a
Blanco-Gomez A et al (2020) Stromal SNAI2 Is required for ERBB2 breast cancer progression. Cancer Res 80:5216–5230. https://doi.org/10.1158/0008-5472.CAN-20-0278
Cai Y, Yu X, Hu S, Yu J (2009) A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinform 7:147–154. https://doi.org/10.1016/S1672-0229(08)60044-3
Chai S, Li ZK, Liu R et al (2020) The role of miRNA-155 in monocrotaline-induced pulmonary arterial hypertension through c-Fos/NLRP3/caspase-1. Mol Cell Toxicol 16:311–320
Chen L, Wang X, Ji C, Hu J, Fang L (2020) MiR-506-3p suppresses papillary thyroid cancer cells tumorigenesis by targeting YAP1. Pathol Res Pract 216:153231. https://doi.org/10.1016/j.prp.2020.153231
Cho ES, Kang HE, Kim NH, Yook JI (2019) Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res 42:14–24. https://doi.org/10.1007/s12272-018-01108-7
Cobaleda C, Perez-Caro M, Vicente-Duenas C, Sanchez-Garcia I (2007) Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu Rev Genet 41:41–61. https://doi.org/10.1146/annurev.genet.41.110306.130146
Cui X, Zhu H, Huang J (2020) Nomogram for predicting lymph node involvement in triple-negative breast cancer. Front Oncol 10:608334. https://doi.org/10.3389/fonc.2020.608334
da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC (2020) Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol 145:102855. https://doi.org/10.1016/j.critrevonc.2019.102855
DeSantis CE et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438–451. https://doi.org/10.3322/caac.21583
Elias AD (2010) Triple-negative breast cancer: a short review. Am J Clin Oncol 33:637–645. https://doi.org/10.1097/COC.0b013e3181b8afcf
He J et al (2016) MicroRNA biogenesis pathway genes polymorphisms and cancer risk: a systematic review and meta-analysis. PeerJ 4:e2706. https://doi.org/10.7717/peerj.2706
Hu FY et al (2016) miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. J Huazhong Univ Sci Technol Med Sci 36:839–845. https://doi.org/10.1007/s11596-016-1672-x
Hu CY, You P, Zhang J, Zhang H, Jiang N (2019) MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4. Eur Rev Med Pharmacol Sci 23:5133–5138. https://doi.org/10.26355/eurrev_201906_18177
Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159. https://doi.org/10.1002/emmm.201100209
Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17:173–176. https://doi.org/10.1177/107327481001700305
Jamdade VS et al (2015) Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol 172:4228–4237. https://doi.org/10.1111/bph.13211
Jiang L, Zhu J (2020) Review of MiRNA-disease association prediction. Curr Protein Pept Sci. https://doi.org/10.2174/1389203721666200210102751
Li W et al (2020) Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. Genes Dev 34:1310–1315. https://doi.org/10.1101/gad.339804.120
Liang TS et al (2019) MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/beta-catenin signaling pathway by down-regulating LHX2. J Exp Clin Cancer Res 38:97. https://doi.org/10.1186/s13046-019-1023-4
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
Luhur A, Kumar JP (2008) Advances in microRNA biology. Fly (austin) 2:123–124. https://doi.org/10.4161/fly.6330
Martignetti L et al (2015) Detection of miRNA regulatory effect on triple negative breast cancer transcriptome. BMC Genomics 16:S4. https://doi.org/10.1186/1471-2164-16-S6-S4
Mohr AM, Mott JL (2015) Overview of microRNA biology. Semin Liver Dis 35:3–11. https://doi.org/10.1055/s-0034-1397344
Panico A et al (2020) The influence of lifestyle factors on miRNA expression and signal pathways: a review. Epigenomics. https://doi.org/10.2217/epi-2020-0289
Sabit H et al (2020) Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol 157:103196. https://doi.org/10.1016/j.critrevonc.2020.103196
Shen M et al (2020) A review of current progress in triple-negative breast cancer therapy. Open Med (wars) 15:1143–1149. https://doi.org/10.1515/med-2020-0138
Sohn S-H, Sul HJ, Choi Y, Lee S, Kim BJ, Kim HS, Koh Y, Zang DY (2021) An integrated mRNA–microRNA regulatory network identified INHBA and has-miR-135a-5p as predictors of gastric cancer recurrence. Mol Cell Toxicol 17:213–220
Tian X, Tao F, Zhang B, Dong JT, Zhang Z (2018) The miR-203/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3beta/beta-CATENIN signal pathway. IUBMB Life 70:224–236. https://doi.org/10.1002/iub.1720
Volovat SR et al (2020) MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a review. Front Oncol 10:526850. https://doi.org/10.3389/fonc.2020.526850
Wang Y et al (2019a) MiR-506-3p suppresses the proliferation of ovarian cancer cells by negatively regulating the expression of MTMR6. J Biosci 44
Wang D, Bao F, Teng Y, Li Q, Li J (2019b) MicroRNA-506-3p initiates mesenchymal-to-epithelial transition and suppresses autophagy in osteosarcoma cells by directly targeting SPHK1. Biosci Biotechnol Biochem 83:836–844. https://doi.org/10.1080/09168451.2019.1569496
Wang Z, Li Y, Kuang X, Guo F, Lang T, Mao M, Zhang X, Yang H (2020) Anti-proliferation and pro-apoptosis effects of miR-582-5p in chronic lymphocytic leukemia via targeting HNRNPA1 and suppression of NF-κB. Mol Cell Toxicol 17:357–365
Wu L, Chen Z, Xing Y (2018) MiR-506-3p inhibits cell proliferation, induces cell cycle arrest and apoptosis in retinoblastoma by directly targeting NEK6. Cell Biol Int. https://doi.org/10.1002/cbin.11041
Xia XY et al (2020) MicroRNA-506-3p inhibits proliferation and promotes apoptosis in ovarian cancer cell via targeting SIRT1/AKT/FOXO3a signaling pathway. Neoplasma 67:344–353. https://doi.org/10.4149/neo_2020_190517N441
Xu J, Wu KJ, Jia QJ, Ding XF (2020) Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B 21:673–689. https://doi.org/10.1631/jzus.B1900709
Yang Z et al (2017) Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression. Mol Cancer 16:163. https://doi.org/10.1186/s12943-017-0732-6
Zhang Z et al (2011) Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2:782–791. https://doi.org/10.1177/1947601911429743
Zhang Y, Xu HY, Dai JJ (2021) MiR-193b enhanced proliferation and migration and inhibits apoptosis through targeting RAB7A in osteosarcoma cel. Mol Cellul Toxicol 17:69–78
Zhou W, Gross KM, Kuperwasser C (2019) Molecular regulation of Snai2 in development and disease. J Cell Sci. https://doi.org/10.1242/jcs.235127
Acknowledgements
None.
Author information
Authors and Affiliations
Contributions
XZ and XB designed the study and performed the experiments. WL and XG validated the results. XW and BL wrote the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
Xuye Zhao declares that she has no conflict of interest. Xiangdong Bai declares that he has no conflict of interest. Weina Li declares that she has no conflict of interest. Xuezhen Gao declares that she has no conflict of interest. Xiaoli Wang declares that she has no conflict of interest. Bin Li declares that he has no conflict of interest.
Ethical approval
The experiments using human tissues were approved by the Ethics Committee of Taiyuan Central Hospital. All the involved participants provided written informed consents.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhao, X., Bai, X., Li, W. et al. microRNA-506-3p suppresses the proliferation of triple negative breast cancer cells via targeting SNAI2. Mol. Cell. Toxicol. 17, 513–522 (2021). https://doi.org/10.1007/s13273-021-00160-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13273-021-00160-7